8-KEarnings & ResultsExhibits & Filings

PFIZER INC 8-K Report, Financial Results (Apr 30, 2019)

Filed April 30, 2019For Securities:PFE

Summary

Pfizer Inc. (PFE) filed an 8-K on April 30, 2019, to announce its first quarter 2019 financial results. The report primarily furnished a press release detailing these results, offering investors an update on the company's operational and financial performance for the period ending April 29, 2019. While the filing itself is procedural, the attached press release contains the substantive financial data investors would focus on. The key takeaway for investors is the disclosure of Pfizer's Q1 2019 financial performance, which is crucial for assessing the company's ongoing business health, revenue generation, and profitability trends. Investors should review the furnished press release for specific metrics such as revenue, earnings per share (EPS), guidance, and segment performance, as these provide the most direct insight into the company's current operational status and future outlook.

Key Highlights

  • 1Pfizer announced its first quarter 2019 financial results on April 30, 2019.
  • 2The 8-K filing primarily served to furnish a press release containing the Q1 2019 financial results.
  • 3The information is incorporated by reference from Exhibit 99, the press release.
  • 4The filing pertains to the financial period ending April 29, 2019.
  • 5Investors are directed to the press release for detailed financial performance information.
  • 6The filing clarifies that the furnished information is not deemed 'filed' for certain SEC liability purposes.

Frequently Asked Questions

The main purpose of this 8-K filing is to formally announce and provide access to Pfizer's first quarter 2019 financial results through an attached press release (Exhibit 99).

The detailed financial results for Pfizer's first quarter of 2019 are contained within the press release furnished as Exhibit 99 to this 8-K filing.

No, the 8-K filing itself does not contain the specific financial figures. It only references and incorporates by reference the press release (Exhibit 99) where these details are presented.

This 8-K filing does not explicitly state new guidance or outlook. Investors would need to review the content of the furnished press release (Exhibit 99) to find any such information provided by Pfizer for Q1 2019.